Why Is ASTRAZENECA PLC (AZN) Stock Moving Today?

AZN stock is moving higher in early trading on July 27 after AstraZeneca reported second-quarter 2026 results that beat expectations. Core earnings per share rose to $2.63, exceeding the $2.48 forecast. The company attributed the performance to strong sales in its oncology division and reaffirmed its full-year and 2030 revenue and earnings guidance.

What Happened

AstraZeneca reported Q2 2026 results that demonstrated robust performance in its core operations. The company’s experimental cancer treatment, sonesitatug vedotin, showed a statistically significant improvement in overall survival for patients with advanced gastric cancers. This result reinforced the company’s long-term growth strategy and its focus on oncology. AstraZeneca also reported 6% revenue growth in the first half of 2026, driven by key product launches and regulatory approvals. The company confirmed its mid-to-high single-digit revenue growth and low double-digit core earnings per share growth guidance for the full year.

The stock opened with a 1.6% gap up from the previous close, reflecting the positive reception of the earnings report and the company’s continued progress in its drug development pipeline.

What The Data Shows

AZN opened at $171.91 and reached an intraday high of $172.05 before retreating slightly. The stock last traded at $170.98, with volume so far at 0.0M shares, which is 0.0x the 3-month average. The stock has traded within a 52-week range of $71.49 to $212.71. Over the last 8 sessions, the stock has gained 0.5%. The company’s fundamentals include a market cap of $261.8B, a P/E ratio of 25.5, and a 9.9% year-to-date revenue increase. Recent insider transactions include a $2.2M sale by Sharma Mani on May 20, while recent congressional trades show purchases by Alan Armstrong and Gilbert Cisneros.

What To Watch

AstraZeneca has not scheduled earnings for the near term, but investors will continue to monitor the company’s progress in oncology and the performance of its key drug launches. Coverage breadth remains strong, with 20 stories from 13 sources in the last 36 hours.